Song Z, et al. - This study was performed on anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1)-rearranged patients of lung adenocarcinoma without epidermal growth factor receptor (EGFR) mutation. The goal was to gain a better understanding of the clinicopathological characteristics, coexistence and treatment of this patient population. An elevated frequency of ALK and ROS1 rearrangements in EGFR-wild-type patients was reported and, data indicated that the phenomenon of coexisting ALK/ROS1 has remained extremely rare. Notably, correlation of the rearrangements of ALK/ROS1 with age, smoking status, expressions of TTF1 & napsin A and solid predominant adenocarcinoma subtype was evident.